Allergan Has $20 Billion for Pharma Deals; China Deals Possible

Allergan, known for its Botox and ophthalmology products, is looking for deals in China and Asia. The company wants to add growth products in its core specialties of medical aesthetics, dermatology and eye care, Allergan CEO Brent Saunders told Bloomberg in a Shanghai interview. Allergan has the money to spend: it is selling off $40 billion of generic drug assets to Teva, and will have $20 billion for IP, R&D assets and M&A, said Saunders. Previously, Allergan has formed at least one China deal: an NPS partnership with Rugen Therapeutics of Suzhou's BioBay Park. More details.... Stock Symbols: (NYSE: AGN) (NYSE: TEVA) Share this with colleagues: // //